This is a working overview of dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-03. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Due to disagreements between Banting and MacLeod, there was ill will generated within the team. The Nobel Prize for Medicine was awarded to Banting and MacLeod in 1923. Feeling that Best had been overlooked in the award, Banting shared his portion with Best. In response, MacLeod shared his portion with Collip. Nonetheless, Collip is often overlooked as a co-discoverer of insulin, in part due to Best's public relations campaign that downplayed Collip's crucial role. Following this early success, Collip returned to Edmonton to take up a position as Head of the new Department of Biochemistry, and to pursue his own studies on hormone research. In 1928 he was recruited to McGill University in Montreal by his former graduate advisor, Archibald Macallum. Collip served as Chair of McGill's Department of Biochemistry from 1928 to 1941. From 1947 to 1961, Collip was appointed Dean of Medicine at the University of Western Ontario. He is regarded as a pioneer of endocrine research. He did pioneering work with the parathyroid hormone (PTH). He died on June 19, 1965, at the age of 72.
The development of Vampire: The Masquerade – Bloodlines began at Troika Games in November 2001. The developers wanted to put a role-playing game in a first-person setting, believing that the genre had become stale. Troika approached publisher Activision with its idea; Activision suggested using the Vampire: The Masquerade license used a year earlier in Nihilistic Software's Vampire: The Masquerade – Redemption, which had experienced sufficient success to merit a sequel. Instead of developing a sequel to Redemption, the development team researched the White Wolf property, including the game's rules and storylines. Troika was a small game studio with five developers and a total staff of thirty-two (including lead writer Brian Mitsoda, who joined the team less than a year after development began). Although some preliminary designs and levels were completed, much of the work was abandoned or redeveloped. Troika wanted to make a 3D game but was uncertain whether to build a new game engine or license an existing one and whether to use first- or third-person. At that time, the Source game engine was being built by Valve. Valve employee Scott Lynch approached Troika about using the engine, and it was the first external team to use it. Troika chose Source for its facial animation and lip-synching system since it wanted players to speak to the characters face-to-face.
=== 2026 Iran war === Following the assassination of Ali Khamenei during the 2026 Iran war, Badr Organization leader Hadi al-Amiri pledged allegiance to the new supreme leader of Iran, Mojtaba Khamenei.
=== UK Parliament === The borough is included in three parliamentary constituencies: Brent East, Brent West and Queen's Park and Maida Vale – which includes part of the City of Westminster. These were created by the 2023 review of Westminster constituencies, superseding the three previous constituencies of Brent North, Brent Central and Hampstead and Kilburn, which included part of the London Borough of Camden. Before the 2010 general election Brent was divided into three constituencies contained wholly within the borough – Brent South, Brent East and Brent North.
Sources: en.wikipedia.org
== Composition == The military was mostly composed of white South Africans, who alone were subject to conscription. The permanent force of the Army was 85% Afrikaans speaking. However, black South Africans were the second largest group, and Asians and Coloured citizens with mixed ancestry were eligible to serve as volunteers, several attaining commissioned rank. From 1971 onwards, several black battalions were raised in the Infantry and Service Corps on a tribal basis, most black soldiers serving in these exclusive tribal battalions, which had black NCOs but white commissioned officers. The first black personnel were accepted into commissioned ranks only from 1986, and then only for serving black soldiers and NCOs. The regular Commission would not be open for Bantus until 1991, and then again they would serve only in black units or Support/Service Support units, to avoid having position of authority over white combat arms personnel. The first black officer to be promoted to lieutenant colonel rank and have command over a battalion sized unit was appointed in February 1994. However, black officer candidates from the various Homeland Forces and from South West Africa/SWATF had been accepted since 1981. Units such as the 32 Battalion incorporated many black volunteers, as did the 101 Battalion. Conscription was opposed by organisations such as the End Conscription Campaign, but overall, white morale remained high—as indicated by the few recruits tried for serious disciplinary offences.
== Glutathione == As the key substrate in GST-mediated reactions, glutathione is one of the most conserved reducing agents in bacterial cells. In its reduced form, glutathione plays a key role in the regulation of reactive oxygen species (ROS) in the cell. ROS are specific to aerobic cells and are usually produced in their metabolic processes. They function to maintain a dynamic balance under normal conditions, acting as intracellular and extracellular signaling molecules. The regulation of levels of ROS, levels of oxidized and reduced glutathione and other thiols, and antioxidant enzymes (such as GSTs and glutathione reductase) are important in determination of the most stable conditions for redox control, or for activation of apoptosis. Glutathione reductase is another enzyme that helps maintain cellular redox homeostasis by maintaining the supply of reduced glutathione. Without glutathione in its reduced form, glutathione transferases are not able to utilize it as a substrate in redox reactions. Glutathione contains a significant amount of cysteine residues, which contributes to its nature of being readily oxidized. The -SH groups on these residues act as strong nucleophiles, which can conjugate with a variety of molecules, including other glutathione molecules. Sulfur itself is able to exist in several different oxidation states; this redox flexibility combined with its strong nucleophilic properties allows glutathione to oxidize/readily pick up electrons from reactive oxygen species. Glutathione transferases play a key role in catalyzing such reactions.
The beta sheet (β-sheet, also β-pleated sheet) is a common motif of the regular protein secondary structure. Beta sheets consist of beta strands (β-strands) connected laterally by at least two or three backbone hydrogen bonds, forming a generally twisted, pleated sheet. A β-strand is a stretch of polypeptide chain typically 3 to 10 amino acids long with backbone in an extended conformation. The supramolecular association of β-sheets has been implicated in the formation of the fibrils and protein aggregates observed in amyloidosis, Alzheimer's disease and other proteinopathies.
Sources: en.wikipedia.org
==== Analysis of Nidogen-1 interacting with Laminin γ1 ==== Laminin's are non-collagenous proteins found in basement membranes and form networks through non-covalent self-interactions. Nidogens (also known as entactins) are sulfated monomeric glycoproteins that are ubiquitously present in basement membranes of higher organisms. Nidogens help with the formation of the basement. With both laminins and nidogens present, both interact with each other to have a stoichiometry relationship of 1:1 in a complex. In order to study the short arm of laminin γ1, photo methionine introduced both to nidogen-1, laminin γ1 LEb2-4, and laminin γ1 short arm to see if this photo-cross linking method could map out the structure. MS/MS analysis was done before cross-linking to find only 13-25% of methionine's had been incorporated, but once UV-A-induced or another cross-linker, BS2G-mediated cross-linked (a homobifunctional cross-linker), the percentage of photo-methionine's had increased to 35%. Both cross-linkers had shown extra structural insight both computationally and experimentally to help with understanding the functions.
Several critics complained about the required usage of the program Steam, the requirement to create an account, register the products, and permanently lock them to the account before being allowed to play, along with installation difficulties and lack of support.
Hydrogen isotope biogeochemistry (HIBGC) is the scientific study of biological, geological, and chemical processes in the environment using the distribution and relative abundance of hydrogen isotopes. Hydrogen has two stable isotopes, protium 1H and deuterium 2H, which vary in relative abundance on the order of hundreds of permil. The ratio between these two species can be called the hydrogen isotopic signature of a substance. Understanding isotopic fingerprints and the sources of fractionation that lead to variation between them can be applied to address a diverse array of questions ranging from ecology and hydrology to geochemistry and paleoclimate reconstructions. Since specialized techniques are required to measure natural hydrogen isotopic composition (HIC), HIBGC provides uniquely specialized tools to more traditional fields like ecology and geochemistry.
=== Carbon fixation === C4 photosynthesis, one of the three major carbon-fixing biochemical processes, has arisen independently up to 40 times. About 7,600 plant species of angiosperms use C4 carbon fixation, with many monocots including 46% of grasses such as maize and sugar cane, and dicots including several species in the Chenopodiaceae and the Amaranthaceae.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.